Jan 11, 2021 / 02:10PM GMT
Jessica Macomber Fye - JPMorgan Chase & Co, Research Division - Analyst
Good morning, everyone. My name is Jess Fye. I'm one of the senior Biotech Analysts at JPMorgan. And we're continuing the JPMorgan Healthcare Conference this morning with Deciphera.
I'm joined by the company's, CEO, Steve Hoerter, who's going to tell you a bit about the business and then we're going to move on to Q&A.
When we go to Q&A, instead of moving to the Yorkshire room, like we usually do in San Francisco, you're going to use the blue ask-a-question button, that's going to send the questions to me on a portal, and then I can use those to ask management, so you can hear the responses.
But let's get started. Steve, over to you.
Steven L. Hoerter - Deciphera Pharmaceuticals, Inc. - President, CEO & Director
Great. Yes, thanks, Jess, and thanks for the kind introduction. Good morning, everyone. Really excited to be here this morning and have an opportunity to provide an update on the tremendous progress that we've made at Deciphera over the
Deciphera Pharmaceuticals Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 11, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers